Ocuphire Pharma, Inc. (OCUP)

$3.22

-0.04 (-1.23%)
Rating:
Recommendation:
-
Symbol OCUP
Price $3.22
Beta -0.165
Volume Avg. 0.21M
Market Cap 66.999M
Shares () -
52 Week Range 1.78-4.43
1y Target Est -
DCF Unlevered OCUP DCF ->
DCF Levered OCUP LDCF ->
ROE -135.62% Strong Sell
ROA -153.53% Strong Sell
Operating Margin -
Debt / Equity 22.66% Neutral
P/E -2.23 Sell
P/B 5.56 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest OCUP news


Healthcare
Biotechnology
NASDAQ Capital Market

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.